Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quality of life in patients <=70 years of age with chronic lymphocytic leukemia treated frontline with ibrutinibrituximab versus fludarabine cyclophosphamide rituximab: Analysis from ECOG-ACRIN E1912
    Meeting Abstract

    Pophali, P. A.; Wang, X. V.; Zhao, F.; Kay, N. E.; Hanson, C. A.; Thomas, M. L.; O'Brien, S. M.; Barrientos, J.; Paietta, E. M.; Leis, J. F.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with myeloid malignancies
    Meeting Abstract

    Patel, M. R.; Monga, V.; Jauhari, S.; Stevens, D.; Masarova, L.; McKean, M.; Mauro, D.; Viscusi, J.; Scherle, P.; Bhagwat, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Ivosidenib (IVO) in combination with azacitidine (AZA) in newly diagnosed (ND) older patients with IDH1 R132-mutated acute myeloid leukemia (AML) induces high response rates: A phase 2 sub-study of the beat AML master trial
    Meeting Abstract

    Patel, P.; Ruppert, A. S.; Borate, U.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Arellano, M. L.; Schiller, G. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of allogeneic hematopoietic cell transplantation (HCT) as consolidation following CD19 chimeric antigen receptor (CAR) T cell therapy for treatment of relapsed acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Park, J. H.; Nikiforow, S.; Kim, S.; Hu, Z. H.; Moskop, A.; Ahmed, S.; Abid, M. B.; Badar, T.; Bredeson, C.; Brown, V.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • COVID-19 in patients with chronic myeloid leukemia: Poor outcomes for patients with comorbidities, older age, advanced phase disease, and those from low-income countries: An update of the candid study
    Meeting Abstract

    Pagnano, K. B.; Kok, C. H.; Mauro, M. J.; Cortes, J. E.; Evans, N.; Jiang, Q.; Milojkovic, D.; Moiraghi, B.; Nicolini, F. E.; Ongondi, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The impact of pacritinib on myelofibrosis symptoms in patients with moderate and severe thrombocytopenia: A retrospective analysis of patients in the PERSIST-2 study
    Meeting Abstract

    Palmer, J. M.; Mesa, R. A.; Oh, S. T.; Rampal, R.; Buckley, S. A.; Roman-Torres, K.; Verstovsek, S.; Mascarenhas, J.; Vannucchi, A. M.; Kiladjian, J. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Maximal tolerated dose determined for venetoclax in combination with liposomal vincristine in patients with relapsed or refractory ph- negative T-cell or B-cell acute lymphoblastic leukemia: Results of phase 1 portion of ECOG-ACRIN EA9152
    Meeting Abstract

    Palmisiano, N.; Lee, J. W.; Claxton, D. F.; Paietta, E.; Alkhateeb, H. B.; Park, J. H.; Podoltsev, N.; Atallah, E. L.; Schaar, D. G.; Dinner, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Allogeneic transplantation in fit older adults is feasible and encouragingly efficacious. Post remission data from the prospective ECOG-ACRIN (E2906) clinical study
    Meeting Abstract

    Ofran, Y.; Sun, Z.; Rowe, J. M.; Claxton, D. F.; Tallman, M. S.; Arber, D. A.; Melnick, A.; Levine, R. L.; Paietta, E.; Godwin, J. E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Enrollment characteristics and outcomes of Hispanic and Black AYA ALL patients enrolled on a US Intergroup clinical trial: A comparison of the CALGB 10403 (alliance) cohort with us population-level data
    Meeting Abstract

    Muffly, L.; Yin, J.; Jacobson, S.; Advani, A.; Luger, S. M.; Tallman, M. S.; Litzow, M. R.; Foster, M. C.; Appelbaum, F. R.; Larson, R. A.; more...
    Blood (2021)

    Fulltext@MSK | Save